P.0812 Reducing the cognitive burden of prophylactic brain radiotherapy in patients with small cell lung cancer

Ramos, J. Salinas; Lemos, Raquel; Almeida, Sílvia; Ruivo, J.; Pimentel, N.; Gil, Nuno; Oliveira-Maia, A.

doi:10.1016/j.euroneuro.2021.10.672

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another randomized phase III trial suggested comparable risks of NCF impairment in patients with SCLC between the two groups, implying that hippocampus sparing may be unnecessary ( 8 ). While HA-CRT has been shown to protect against radiation-induced memory loss, it does not prevent deterioration in the executive zone of NCF ( 9 ). The debate regarding whether hippocampal sparing increases the risk of BM within the HA zone continues.…”

Section: Introductionmentioning

confidence: 99%

Cranial radiation therapy with hippocampus avoidance in lung cancer treatment: systematic review and meta-analysis

Zheng,

You,

Feng

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundThe role of cranial radiation therapy with hippocampus avoidance (HA-CRT) in neurocognitive function (NCF), brain metastasis (BM), and overall survival (OS) in lung cancer remains unclear.MethodsA meta-analysis was conducted to evaluate the impact of HA-CRT in lung cancer. Data from studies on hippocampal-avoidance prophylactic cranial irradiation (HA-PCI) and whole brain radiotherapy (HA-WBRT) were pooled.ResultsA total of 14 studies, including 5 randomized controlled trials, were included. The focus of NCF was mainly via the Hopkins Verbal Learning Test—Revised or the Free and Cued Selective Reminding Test. At 6 months post-radiotherapy, the pooled proportion of participants with decline in the performance of total recall, delayed recall, and discrimination in neurocognitive tests were 0.22 (95% CI 0.15, 0.29), 0.20 (95% CI 0.13, 0.27), and 0.14 (95% CI 0.05, 0.24) respectively. After 12 months, the proportion were 0.16 (95% CI 0.08, 0.23), 0.10 (95% CI 0.04, 0.16), and 0.04 (95% CI 0, 0.09) respectively. For HA zone relapse, the RR of HA-CRT versus CRT was 2.72 (95% CI 0.53, 13.87), and for 2-year BM, it was 1.20 (95% CI 0.82, 1.75). Regarding HA-PCI in SCLC, the 1-year BM rate was 0.12 (95% CI 0.07, 0.17), and the 2-year BM rate was 0.20 (95% CI 0.16, 0.25). For HA-WBRT in NSCLC with BM, the 2-year intracranial progression rate was 0.38 (95% CI 0.13, 0.62). There was no significant difference in OS between HA-CRT and CRT.ConclusionsHA-CRT appears to be safe in lung cancer, but it may not outperform conventional CRT. Larger RCTs comparing HA-CRT and CRT are warranted.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022360890, identifier CRD42022360890.

show abstract

Section: Introductionmentioning

confidence: 99%